Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorGöteborg University
About this trial
This is a prospective randomized controlled trial where quality of life and the effectiveness of treatment will be evaluated in 80 patients with confirmed unilateral primary aldosteronism ,randomly assigned to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone.
Eligibility criteria
Qualifiers
Patients with confirmed unilateral PA
Age 18-70 years
Candidate for surgical treatment
No contraindications for minimally invasive surgery or treatment with MRA
Disqualifiers
Unwilling or unable to undergo surgery
Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)
Impaired renal function with eGFR <45 ml/min/1,73m2
P-cortisol >138 nmol/L following 1-mg overnight dexamethasone suppression test.
Trial design
Treatments tested in this trial
- Unilateral adrenalectomy
- Medical treatment (eplerenone)
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov